Surveillance of invasive bacterial disease in Alaska, 2009

• Other Authors: National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Division of Preparedness and Emerging Infections. Arctic Investigations Program.
• Language: English
• Subjects: Bacterial Infections; Disease Notification; Haemophilus Influenzae; Neisseria Meningitidis; Pneumococcal Infections; Public Health Surveillance; Streptococcal Infections; Anchorage; Arctic; Alaska
• Online Access: http://stacks.cdc.gov/view/cdc/43838/

The Centers for Disease Control and Prevention's Arctic Investigations Program (AIP) in Anchorage, Alaska, maintains a statewide surveillance system for invasive diseases caused by Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, and groups A and B streptococci. Laboratories throughout the state are requested to send to AIP any isolates of these organisms recovered from a blood culture, CSF, or other normally sterile site in an Alaska resident. Isolate identification is confirmed and, when appropriate, serotyped and tested for antimicrobial susceptibility. The objectives of this system are to provide information on disease rates within the state, monitor the emergence of antimicrobial resistance, and to monitor the effectiveness of implemented vaccine programs, such as the 23-valent pneumococcal polysaccharide vaccine, the pneumococcal conjugate vaccine and Haemophilus influenzae type b vaccines. In 2009, the total numbers of cases of invasive disease caused by these organisms reported to AIP were 148 S. pneumoniae, 21 H. influenzae, 5 N. meningitidis, 35 group A Streptococci (GAS) and 31 group B Streptococci (GBS). Summary -- Introduction -- Invasive Pneumococcal Disease -- Invasive Haemophilus influenzae -- Invasive Neisseria meningitidis -- Invasive Group A Streptococcus -- Invasive Group B Streptococcus -- References -- Appendix: MIC Interpretive Standards Definitions.